ALP Bio Raises €1.9M Pre-seed

ALP Bio AG, based in Schlieren, Switzerland, is developing an AI platform that combines human tonsil organoid biology with generative AI to detect and reduce anti-drug antibody (ADA) immunogenicity risk earlier in the drug development lifecycle. The company closed a €1.9 million pre-seed financing round.

Investors

Munich VC 42CAP led the round. Additional participation came from Venture Kick and strategic angel investors, including Ajira Ventures.

ALP Bio Use of Funds

The pre-seed capital will be deployed to expand immune organoid lab capacity, launch early pharma partner projects, and build out teams in Switzerland and the United States. This includes expanding organoid throughput and automation, and growing scientific and commercial capacity across Switzerland and San Diego, USA.

About ALP Bio

Founded in 2025 by CEO Dr. Christian Vahlensieck alongside co-founders Anatol Ehrlich, Punit Mehra, and Lucas Schaus, ALP Bio is building a platform that fuses human immune organoid readouts with generative AI. Its mission is to surface immunogenicity risk earlier in antibody development, helping antibody developers identify, understand, and reduce immunogenicity risk earlier in drug development.

Funding Details

Company: ALP Bio
Raised: €1.9M
Round: Pre-seed
Funding Date: April 29, 2026
Lead Investor: 42CAP
Additional Investors: Venture Kick, Ajira Ventures
Software Category: Biotech AI, Drug Discovery AI
Company Website: https://alp.bio
Source: https://www.sci-tech-today.com/news/alp-bio-raises-1-9m/